BPC 157 medication fully counteracts these disturbances ( p 0.05, at least, vs
Chen P, Han Y, Wang L, Zheng Y, Zhu Z, Zhao Y, et al
Disclosures: Wen Zhang: Nothing to Disclose, Wenyue Wu: Nothing to Disclose, Ning Zhang: Nothing to Disclose, Hong Li: Nothing to Disclose, Yameng Sun: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Hui Han: Nothing to Disclose, Shuyan Chen: Nothing to Disclose, Anjian Xu: Nothing to Disclose, Sai Santosh Babu Komakula: Nothing to Disclose, Chao Wang: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Qi Han: Nothing to Disclose, Xuzhen Yan: Nothing to Disclose, Aiting Yang: Nothing to Disclose, Natalia Nieto: Nothing to Disclose, Hong You: Nothing to Disclose, Wei Chen: Nothing to Disclose 2043 NOVEL BLOOD-BASED BIOMARKER MODEL FOR DIAGNOSIS OF HEPATIC FIBROSIS IN MASLD Eveline Gart Lars Verschuren 1 Anne Mak 2 Andre Boonstra 3 Joanne Verheij 4 Lise Lotte Gluud 5 Adriaan Holleboom 2 Maarten Tushuizen 6 , 1 TNO, 2 Amsterdam UMC, 3 Erasmus University Medical Center, 4 Academic Medical Center, 5 Copenhagen University - Hvidovre Hospital, 6 LUMC Background: Considering the escalating prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and related fibrosis, accurate non-invasive biomarkers for diagnosis and staging of fibrosis are urgently needed
According to Cleveland Clinic, hypokalemia is defined as a serum potassium level below 3.5 mmol/L , and severe cases below 2.5 mmol/L can lead to life-threatening ventricular arrhythmias
